Our long-serving CFO, Sandy Mahatme, is retiring from Sarepta this month. He’s had a big impact on our transformation and his outsized personality will be missed. Today we celebrate his accomplishments and extend our gratitude. pic.twitter.com/CPbFdPzprM
— Sarepta Therapeutics (@Sarepta) June 30, 2020
SRPT CEO, Doug Ingram, shared his thoughts with @BusinessInsider on how the #COVID19 pandemic is transforming the #biotech industry. Read the full story [subscription required]: https://t.co/E35JOw77v2 https://t.co/yYKAInozOg pic.twitter.com/n4M7vUPl1M
— Sarepta Therapeutics (@Sarepta) May 12, 2020
Today is World Duchenne Awareness Day. #Duchenne is a rare, genetic form of #musculardystrophy that primarily affects males, but can affect females, and can have a devastating impact individuals and families. Join us in raising awareness for #WDAD2020. pic.twitter.com/t7JyoI1YsT
— Sarepta Therapeutics (@Sarepta) September 7, 2020
Today we announced a collaboration with @UF to enable cutting-edge research for novel #geneticmedicine, through the funding of multiple innovative research programs. Read our press release to learn more: https://t.co/4EMlnqRsRX SRPT pic.twitter.com/XriebPvJxE
— Sarepta Therapeutics (@Sarepta) August 11, 2020
This morning, SRPT announced our SRP-9001 investigational gene transfer therapy for the treatment of #Duchenne #MuscularDystrophy received Fast Track designation from the FDA. Read the full press release: https://t.co/4fKjYV6SvT pic.twitter.com/8EBEwd4SOi
— Sarepta Therapeutics (@Sarepta) July 24, 2020
We announced an agreement w/ Hansa Biopharma to develop and promote imlifidase as a pre-treatment to enable SRPT gene therapy administration in #Duchenne #musculardystrophy and #LimbGirdle muscular dystrophy in patients with pre-existing immunity to AAV. https://t.co/FgTnPKEYDu pic.twitter.com/XlRYatGmNj
— Sarepta Therapeutics (@Sarepta) July 2, 2020
Today we announced our submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for casimersen, for patients with #Duchenne #MuscularDystrophy amenable to skipping exon 45. Read the press release: https://t.co/zB8Rt7g57k pic.twitter.com/Fp3CXokz1P
— Sarepta Therapeutics (@Sarepta) June 26, 2020
Today we announced an agreement with Codiak Bio Sciences to develop engineered exosome therapeutics to deliver #genetherapy, #geneediting and RNA technologies for neuromuscular diseases, potentially offering the ability to deliver genetic materials. https://t.co/iji3sInbtv pic.twitter.com/ysPGQ0oBHX
— Sarepta Therapeutics (@Sarepta) June 22, 2020
Today we announced an agreement with @SelectaBio to develop and commercialize Selecta’s ImmTOR immune tolerance platform, to potentially minimize the formation of neutralizing antibodies to adeno-associated virus (AAV), used to deliver #genetherapies. https://t.co/QJfgBQKw5z pic.twitter.com/W9JWgt8o5P
— Sarepta Therapeutics (@Sarepta) June 18, 2020
Today, Sarepta announced positive expression and functional data from the SRP-9003 gene therapy trial to treat #Limbgirdle #musculardystrophy type 2E. Learn more: https://t.co/HTUdUXg7y5 pic.twitter.com/oSMqppWCx0
— Sarepta Therapeutics (@Sarepta) June 8, 2020
Today is #MPSAwarenessDay. Mucopolysaccharidosis type IIIA (MPS IIIA), or Sanfilippo syndrome type A, is a rare inherited neurodegenerative disorder. Learn more about MPS IIIA and the work we are doing with @LYSOGENE: https://t.co/sYuxyfTkHi #ChaseTheSigns pic.twitter.com/HflSKMnblH
— Sarepta Therapeutics (@Sarepta) May 15, 2020
#BREAKING: Today, we announced a strategic licensing agreement with @Roche for SRP-9001, our investigational #genetherapy candidate for #Duchenne #musculardystophy, in countries outside the US
Learn more: https://t.co/4DDT1kYrzX #SRPT pic.twitter.com/i10Ic0gxrX— Sarepta Therapeutics (@Sarepta) December 23, 2019
Recently, we joined the Duchenne community in celebrating the #FDAapproval of the first newborn screening test kit authorized for #Duchenne #MuscularDystrophy, empowering families with information and potentially early treatment options. https://t.co/uOLRCKjwbY
— Sarepta Therapeutics (@Sarepta) December 19, 2019
#Breaking: US FDA approves new treatment for certain patients with #Duchenne #MuscularDystrophy. This approval is an important milestone that reflects our dedication to finding treatments for all people living with Duchenne. https://t.co/7dhbjy3wCR pic.twitter.com/u2so5ZtcwF
— Sarepta Therapeutics (@Sarepta) December 12, 2019
We are excited to join #TransportationADVANCE with @KendallNow to work with companies and employees across #KendallSquare to find creative solutions to our common #commuting challenges. https://t.co/inZz9jMsH7
— Sarepta Therapeutics (@Sarepta) October 15, 2019
Katherine discusses how she meets the emotional challenges of life with #limbgirdle #musculardystrophy. Read her story: https://t.co/IAKgkQIFx6#LGMDAwareness #LGMD2D pic.twitter.com/4xWuDyfDEl
— Sarepta Therapeutics (@Sarepta) September 30, 2020
Today is #Limbgirdle #musculardystrophy Awareness Day. Check out this infographic to learn more about this rare #neuromuscular disease and share this post to raise awareness. #LgmdDay2020 pic.twitter.com/XRrmbRShC8
— Sarepta Therapeutics (@Sarepta) September 30, 2020
Today we announced two-year follow up results from our investigational micro-dystrophin #genetherapy for the treatment of #Duchenne #musculardystrophy. Learn more: https://t.co/4YhACzOy0y pic.twitter.com/QtdWsTBebw
— Sarepta Therapeutics (@Sarepta) September 28, 2020
Rania, who has a rare disease called #LimbGirdle #MuscularDystrophy, Type 2E, shares how her support team helps her navigate health issues, social life and a successful career in financial data analytics. Read her story here: https://t.co/JDUnX5AuSx pic.twitter.com/krBVH2NMPs
— Sarepta Therapeutics (@Sarepta) September 22, 2020
Throughout the month of September we’re sharing #limbgirdle #musculardystrophy patient stories to shine a light on this community and raise awareness for this #raredisease. Head over to https://t.co/aQJKY7vUCk to check them out.
— Sarepta Therapeutics (@Sarepta) September 21, 2020
We think Stanford University is pretty lucky to have a student like Brian. Read more about him and the other recipients of Route 79, the #Duchenne scholarship program: https://t.co/kUSwlSvmkP pic.twitter.com/YnMUZENqGq
— Sarepta Therapeutics (@Sarepta) September 17, 2020
We often hear about the challenges of getting to a correct #limbgirdle #musculardystrophy diagnosis. Ben and Nikki share their son Kaleb's story, including the diagnostic tests that finally confirmed his LGMD2C diagnosis: https://t.co/FyzaDgu1QZ
— Sarepta Therapeutics (@Sarepta) September 16, 2020
Alex joined SRPT as a summer intern in 2014. Today, his work is instrumental in expanding our scientific capabilities, recently leading a collaboration w/ the University of Florida to enable cutting-edge research for #geneticmedicine. Read the full story: https://t.co/fRXns1z3qI pic.twitter.com/zajFDL4D5Y
— Sarepta Therapeutics (@Sarepta) September 14, 2020
Chris was initially diagnosed w/ #Becker #musculardystrophy, the same condition his brother had. Following a car accident 16 years later, doctors uncovered the truth: He has #limbgirdle muscular dystrophy. Read more about Chris’ winding road to diagnosis: https://t.co/Sdsh2nqAhq pic.twitter.com/VKXAI7goIL
— Sarepta Therapeutics (@Sarepta) September 10, 2020
We just shared a program update related to SRP-9001, our investigational #GeneTherapy for the treatment for #Duchenne #musculardystrophy. Read our press release for more information: https://t.co/f5c8SvtIe0 pic.twitter.com/0sSfB50u3s
— Sarepta Therapeutics (@Sarepta) September 9, 2020
In the Spring of 2018, within a matter of 8 weeks, brothers Caleb and Duncan were both diagnosed with Duchenne muscular dystrophy. Watch their story: https://t.co/DOO82AtFG3 pic.twitter.com/TIxx0uc0MD
— Sarepta Therapeutics (@Sarepta) September 7, 2020
SRPT team members around the world are teaming up with the @JettFoundation to show how we are #StrongerThanDuchenne! #EndDuchenne pic.twitter.com/rqjrz8AfCO
— Sarepta Therapeutics (@Sarepta) September 7, 2020
After 6 months searching for answers, along with genetic tests & a muscle biopsy, doctors diagnosed Austin, then 10, with #limbgirdle #musculardystrophy, type 2D. Read Austin’s story & learn more about the often overlooked signs & symptoms of LGMD: https://t.co/qIbRoUqXOt pic.twitter.com/EKldinsvTo
— Sarepta Therapeutics (@Sarepta) September 3, 2020
Our senior director of Total Rewards joined a group of leaders on the Future of (how we) Work Task Force to find solutions to challenges of #childcare during #COVID19, and share how SRPT is creating a #culture that is supportive of #caregiving. Learn more: https://t.co/sUAbraKwiA pic.twitter.com/HBHCKtBBO0
— Sarepta Therapeutics (@Sarepta) September 2, 2020
What are the chances? All three of the disease areas on which we are focused celebrate awareness days during the month of September. Follow along throughout the month to learn about #Duchenne #musculardystrophy, #limbgirdle muscular dystrophy and #CharcotMarieTooth disease. pic.twitter.com/UhCoX6rSN4
— Sarepta Therapeutics (@Sarepta) September 1, 2020
Today we announced FDA acceptance of our New Drug Application (NDA) seeking accelerated approval for casimersen (SRP-4045), our PMO for patients with #Duchenne #musculardystrophy who are amenable to skipping exon 45 of the dystrophin gene. Learn more: https://t.co/aKHotU8LU7 SRPT pic.twitter.com/L3lfebyodE
— Sarepta Therapeutics (@Sarepta) August 25, 2020
The progress we’ve made, despite the challenges of the #COVID19 pandemic, is a result of the resiliency of our team members, partners, and the patient community – SRPT EVP and Chief Medical Officer, R&D, Gilmore O’Neill on our #Q22020Results call: https://t.co/JWDmR5r44C pic.twitter.com/ndroH2fHts
— Sarepta Therapeutics (@Sarepta) August 7, 2020
As part of our Rare Lessons program, we’re partnering with https://t.co/wsnEOLAK21 to provide free educational plans to enhance rare disease edu in schools. Learn more about how you may be eligible to win a $2500 grant for you and your school: https://t.co/97uGaap33w pic.twitter.com/uEOVQwtFO5
— Sarepta Therapeutics (@Sarepta) August 7, 2020
On our #Q22020Results call, CEO, Doug Ingram, reflects on the progress we’ve made on our mission to transform lives and highlights the people who are making our ambitious vision a reality – the SRPT team, our external partners, and the patient community. https://t.co/JWDmR5r44C pic.twitter.com/VjUxW763uu
— Sarepta Therapeutics (@Sarepta) August 5, 2020
We just announced our Q2 2020 financial results. Read our press release for details: https://t.co/R5gyNKvixM
SRPT #biotech #Q22020Results pic.twitter.com/2q3XzVa9Qb— Sarepta Therapeutics (@Sarepta) August 5, 2020
Excited to be named as a finalist for the 2020 National Xconomy Awards Deal of the Year, for our partnership with @Roche – a partnership that will help us accelerate our mission for those living with #Duchenne #musculardystrophy. #xconAwards SRPT https://t.co/dovmlU1W1I pic.twitter.com/K3o7tc36by
— Sarepta Therapeutics (@Sarepta) August 3, 2020
#RareDisease education is an important part of disease awareness. That’s why we’re launching Rare Lessons, a SRPT-led program intended to promote the development and implementation of rare disease lessons in the K-12 classroom. Learn more: https://t.co/97uGaap33w pic.twitter.com/hawuHTYMBi
— Sarepta Therapeutics (@Sarepta) July 15, 2020
Today we announced the launch of Rare Lessons, a SRPT-led lesson planning competition intended to promote the development and implementation of educational materials to increase #raredisease awareness in the K-12 classroom setting. Learn more: https://t.co/7c0RnbVkGb pic.twitter.com/UEc4NDkpAg
— Sarepta Therapeutics (@Sarepta) July 15, 2020
Our SVP of Global Policy, Government and Patient Affairs, Diane Berry, was recently interviewed on the @patientsrising podcast, discussing the 21st Century Cures Act. pic.twitter.com/ZBq5jRhkch
— Sarepta Therapeutics (@Sarepta) July 2, 2020
What began with a seemingly average foot injury, resulted in Julianna’s years-long journey to her #limbgirdle #musculardystrophy type 2B diagnosis. Today, Julianna focuses on using her experience to help others. Read her story: https://t.co/xsORpLBX6r pic.twitter.com/qTQpKx9gCo
— Sarepta Therapeutics (@Sarepta) June 24, 2020
Each month, we recognize our colleagues who go above and beyond to live our #values with the Cultural Value Awards. Congratulations to the Q4 2019 and Q1 2020 recipients, and thank you for your dedication to our mission to #DragTomorrowIntoToday. pic.twitter.com/fPT4y0DtYv
— Sarepta Therapeutics (@Sarepta) May 26, 2020
SRPT team members have talent. And it’s no surprise, their kids do too! We invited our SRPT extended family to participate in a talent show as a way to stay connected while working from home. Take a look: pic.twitter.com/sEAP16Po1j
— Sarepta Therapeutics (@Sarepta) May 18, 2020
Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome A, affects each person differently, but symptoms often appear before age 1 making disease awareness and education vital to early intervention. Learn more: https://t.co/sYuxyfTkHi #MPSAwarenessDay. pic.twitter.com/XccF7iWhHy
— Sarepta Therapeutics (@Sarepta) May 15, 2020
Today we announced an agreement with @Dyno_Tx to develop next-gen AAV vectors for muscle diseases. With our leadership in rare diseases, we're thrilled to invest in additional innovative approaches to build our #genetherapy engine. Learn more: https://t.co/UzbaKGW9S9 SRPT pic.twitter.com/SMOJtUkF9e
— Sarepta Therapeutics (@Sarepta) May 11, 2020
On yesterday’s #Q12020Results call, CEO, Doug Ingram, speaks to how we are responding to the #COVID19 crisis, while continuing to serve the #raredisease patient communities. Learn more: https://t.co/8qF6zKNwdw pic.twitter.com/K5XkM6dEUw
— Sarepta Therapeutics (@Sarepta) May 7, 2020
Reminder: Forward-looking statements are subject to risks, including those described in SRPT's #Q12020Results and corporate update #PressRelease Tune in here: https://t.co/6RnNTq2TtM
— Sarepta Therapeutics (@Sarepta) May 6, 2020
The Duchenne Family Assistance Program was an idea spawned by a desire to do more. Read why Marissa and Kelly, founders of @TeamJosephInfo and @LHF_EndDuchenne have joined forces to help more families affected by this #raredisease: https://t.co/a3WfQQCLz4 pic.twitter.com/uJC0LgbgAN
— Sarepta Therapeutics (@Sarepta) April 17, 2020
In response to COVID-19, watch a message to the patient community from our CEO, Doug Ingram: https://t.co/lM937MxIX7 pic.twitter.com/0ii3nPjZc0
— Sarepta Therapeutics (@Sarepta) April 14, 2020
We’re proud to fund the @speakfoundation Financial Relief Program, an effort that will assist individuals with #limbgirdle #musculardystrophy #LGMD who are having financial hardships due to COVID-19. Learn more: https://t.co/1MaqRkfodZ pic.twitter.com/TI6GTOqLK5
— Sarepta Therapeutics (@Sarepta) March 31, 2020
SRPT stays home for patients and families impacted by #Duchenne muscular dystrophy, #limbgirdle muscular dystrophy and other #rarediseases. Why do you stay home? @Alnylam @SageBiotech @AlexionPharma @VertexPharma #IStayHomeFor https://t.co/pWQtix3QQY pic.twitter.com/QlKrXF9Cfr
— Sarepta Therapeutics (@Sarepta) March 24, 2020
The situation around #COVID19 is changing every day. Please click on the link below for a statement on how SRPT is supporting patients, providers, employees and communities. https://t.co/1QMPxuJcrJ pic.twitter.com/hnzARcLTfE
— Sarepta Therapeutics (@Sarepta) March 19, 2020
Continuing our commitment to ensure families have access to early diagnosis, we’ve partnered with the @MDAorg and @RTI_Intl to add a test for #Duchenne #musculardystrophy to the Early Check program’s screening panel for North Carolina newborns: https://t.co/l9KaCsAdAO
— Sarepta Therapeutics (@Sarepta) March 3, 2020
"Sarepta values diversity and inclusion, making sure each employee feels they are valued here and supported in every walk of life." Hear from our team members about why they choose to build their careers at SRPT.
Learn more: https://t.co/XbiHB3yfy8 pic.twitter.com/ucfld0afzO
— Sarepta Therapeutics (@Sarepta) March 2, 2020
#Patientcare –is—and will continue to be our driving force: SRPT CCO, Bo Cumbo on yesterday’s #Q4FY19Results call. #Q4Results
Learn more here: https://t.co/Y4VTfAJvhO pic.twitter.com/iFbiU05dRX
— Sarepta Therapeutics (@Sarepta) February 27, 2020
Reminder: Forward-looking statements are subject to risks, including those described in our #Q4FY19Results and corporate update: https://t.co/Li6MYhcuAo SRPT #Q4Results
— Sarepta Therapeutics (@Sarepta) February 26, 2020
We have officially launched our new website! Thank you to the patients and families who generously shared their time and stories.
Take an inside look at how SRPT infused its corporate brand with urgency and optimism on behalf of patients: https://t.co/O9UHj3ZQs4 pic.twitter.com/sdk7N31TjQ
— Sarepta Therapeutics (@Sarepta) February 25, 2020
#RaisingAwareness: Each year, Jonathon films a video of himself singing, this year dedicating his performance to those who have lost their lives to #Duchenne. Help him reach his goal of 20,000 shares before Christmas Day: https://t.co/WbSFSzb9lO pic.twitter.com/lKflHsFjYq
— Sarepta Therapeutics (@Sarepta) December 12, 2019
We are proud to support @HopeforGus and #EverestToEndDuchenne. This team conquered the trek to Mt. Everest base camp where they read the names of almost 600 people who are battling Duchenne or have passed away from this disease. Thank you for raising awareness and inspiring us! pic.twitter.com/gk0ZjVJXfM
— Sarepta Therapeutics (@Sarepta) November 26, 2019
We recently had the pleasure of welcoming @SharonFCallahan, CEO of @tbwaworldhealth, for a discussion sponsored by Sarepta #PRIDE. Thank you, Sharon, for sharing your story and offering insights on fostering a culture of #diversityandinclusion. pic.twitter.com/vfr3MoKvHR
— Sarepta Therapeutics (@Sarepta) November 20, 2019
Each month we recognize SRPT team members who embody our #values with our Cultural Value Awards. Congratulations Q3 recipients and thank you for your dedication to your colleagues and our mission to #DragTomorrowIntoToday. pic.twitter.com/Qp3HjuWJGK
— Sarepta Therapeutics (@Sarepta) November 20, 2019
This morning, we announced a strategic collaboration with #StrideBio, demonstrating our commitment to advancing next-generation capsid technology to further fuel our enduring #genetherapy research engine. Learn more: https://t.co/pcULGitHi9 SRPT pic.twitter.com/bCrp5KN4E2
— Sarepta Therapeutics (@Sarepta) November 14, 2019
On yesterday’s #Q3Results call, SRPT CCO, Bo Cumbo, underscores our commitment to the patient communities – the center of every action we take. Learn more here: https://t.co/KMPviaDDvx pic.twitter.com/IEYobWrG8a
— Sarepta Therapeutics (@Sarepta) November 8, 2019
We just announced our Q3 2019 financial results. Read our press release for details. SRPT #biotech #Q3Results https://t.co/FxMqLaGQrv pic.twitter.com/LcdcdCTmFj
— Sarepta Therapeutics (@Sarepta) November 7, 2019
We had so much fun with Sarepta family and furry friends at our annual #TrickorTreating event. #HappyHalloween from the Sarepta team! pic.twitter.com/fQIAcirdeG
— Sarepta Therapeutics (@Sarepta) October 31, 2019
Today, we announced 9-month functional results from participants in our #genetherapy clinical trial to treat #Limbgirdle #MuscularDystrophy Type 2E #LGMD2E. Read our press release to learn more: https://t.co/xLs0rtz1Yo SRPT pic.twitter.com/QtCRsAfxaA
— Sarepta Therapeutics (@Sarepta) October 4, 2019
We are excited to launch our Return-to-Work program in partnership with @reacHIRE, to support women who are returning to the workforce after time away with exciting opportunities for skill-building and career development in #biotech. https://t.co/HImZEOasaM
— Sarepta Therapeutics (@Sarepta) October 3, 2019
In recognition of #LgmdDay2019, we had the privilege to hear from Pat M. about his experience living with #LGMD. Thank you for sharing your story, Pat. You, along with individuals and families living with this and other #rarediseases, are our inspiration to #DragTomorrowIntoToday pic.twitter.com/uQxCVLUAbx
— Sarepta Therapeutics (@Sarepta) October 1, 2019
Today and every day, we are united with the global #Limbgirdle #musculardystrophy community in raising awareness for #LGMD. #LGMDDay2019 #TogetherWeAreStronger https://t.co/yPxqBdorKb
— Sarepta Therapeutics (@Sarepta) September 30, 2019
Meet another 2019 Route 79, The #DuchenneScholarship recipient! Find out more: https://t.co/MxGrZXIkJo pic.twitter.com/V1xggjA17V
— Sarepta Therapeutics (@Sarepta) September 30, 2019